Domov › Rak prostate › Tennessee › Nashville
Klinične študije za Rak prostate v Nashville, TN
43 študij za Rak prostate išče udeležence na lokacijah v Nashville in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Vključevanje udeležencevFaza 1/2
- GSK Investigational Site, Nashville
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Vključevanje udeležencevFaza 3
- Urology Associates, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 2
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Vključevanje udeležencevFaza 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Vključevanje udeležencevFaza 1
- Tennessee Oncology, Nashville
DESTINY-PANTUMOUR04
Vključevanje udeležencevOpazovalna študija
- Research Site, Nashville
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute, Nashville
- Urology Associates, Nashville
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Vključevanje udeležencevFaza 3
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology Clinic, Nashville
- Tennessee Oncology, PLLC - Nashville Saint Thomas West, Nashville
- in še 7
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Vključevanje udeležencevFaza 1
- Tennessee Oncology, Nashville
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Vključevanje udeležencevFaza 3
- Sarah Cannon Research Institute Oncology Partners, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Vključevanje udeležencevFaza 3
- Research Site, Nashville
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute, Nashville
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Vključevanje udeležencevFaza 2
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Vključevanje udeležencevFaza 3
- SCRI Oncology Partners ( Site 0074), Nashville
- Henry-Joyce Cancer Clinic ( Site 0042), Nashville
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute Oncology Partners, Nashville
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Vključevanje udeležencevFaza 3
- Urology Associates of Nashville, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Center, Nashville
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute, Nashville
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Vključevanje udeležencevFaza 2
- Tennessee Oncology Nashville, Nashville
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Vključevanje udeležencevFaza 1
- SCRI Oncology Partners, Nashville
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Vključevanje udeležencevFaza 3
- Research Site, Nashville
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Vključevanje udeležencevFaza 2
- Sarah Cannon Research Institute, Nashville
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Vključevanje udeležencevFaza 1
- United States Oncology Regulatory Affairs Corporate Office, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Vključevanje udeležencevFaza 2
- Henry-Joyce Cancer Clinic, Nashville
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Vključevanje udeležencevFaza 1
- Sarah Cannon Research, Nashville
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Tennessee Oncology PLLC, Nashville
PSMA PET Combined With MRI for the Detection of PCa
Vključevanje udeležencevFaza 3Vabljeni zdravi prostovoljci
- Urology Associates of Nashville, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Investigative Site #102, Nashville
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Vključevanje udeležencevFaza 3
- Vanderbilt University/Ingram Cancer Center, Nashville
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Vključevanje udeležencevFaza 1
- Urology Associates PC, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Vanderbilt-Ingram Cancer Center, Nashville
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Research Site 136, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Nashville
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Vključevanje udeležencevFaza 3
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Exelixis Clinical Site #6, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Vključevanje udeležencevFaza 1/2
- SCRI Oncology Partners, Nashville
Študije za Rak prostate v drugih mestih
- New York City, NY103 študij
- Houston, TX76 študij
- Los Angeles, CA61 študij
- Boston, MA59 študij
- St. Louis, MO46 študij
- Chicago, IL45 študij
- San Francisco, CA45 študij
- Philadelphia, PA44 študij
- Baltimore, MD43 študij
- Seattle, WA42 študij
- Washington, DC38 študij
- Dallas, TX36 študij
Druge študije v Nashville
- Nemalicelični pljučni rak97 študij
- Rak dojke81 študij
- Metastatski rak70 študij
- Kolorektalni rak69 študij
- Rak (vse vrste)65 študij
- Rak jajčnikov49 študij
- Rak pljuč40 študij
- Ploščatocelični karcinom glave in vratu39 študij
- Rak trebušne slinavke39 študij
- Rak endometrija38 študij
- Melanom33 študij
- Množni mielom32 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.